NCT01545921

Brief Summary

The aim of this study is to culturally adapt and to validate Quality Of Life tools dedicated to the end of life for French cancer patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
179

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2011

Longer than P75 for not_applicable

Geographic Reach
1 country

10 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2011

Completed
8 months until next milestone

Study Start

First participant enrolled

November 11, 2011

Completed
4 months until next milestone

First Posted

Study publicly available on registry

March 7, 2012

Completed
7.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2019

Completed
Last Updated

August 1, 2023

Status Verified

November 1, 2020

Enrollment Period

7.6 years

First QC Date

March 16, 2011

Last Update Submit

July 31, 2023

Conditions

Keywords

Quality Of LifeCancerEnd of lifepalliative setting

Outcome Measures

Primary Outcomes (1)

  • Psychometric validation of QUALE and Missoula Vitas Quality Of Life Index (MVQOLI)

    Both QUALE and MVQOLI have many questions, and each question is evaluated by a number of points. At the end of completion, a score is calculated thanks to number of points and is used to compare the different times completion : * no change of score between the 2 first completion (reproductibility) * change score with baseline * correlation with QLQ-C15 PAL Score * correlation with clinical measure (PS, PPS)

    Up to 3 years

Secondary Outcomes (3)

  • Change in Quality of Life at different times

    Up to 3 years

  • Number of spontaneous questionnaire completions

    Up to 3 years

  • Rate of completion

    Up to 3 years

Study Arms (4)

Arm A

EXPERIMENTAL

Patients will complete QoL questionnaires in the following order : MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death

Other: Quality Of Life questionnaires completion

Arm B

EXPERIMENTAL

Patients will complete QoL questionnaires in the following order : QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death

Other: Quality Of Life questionnaires completion

Arm C

EXPERIMENTAL

Patients will complete QoL questionnaires in the following order : MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death

Other: Quality Of Life questionnaires completion

Arm D

EXPERIMENTAL

Patients will complete QoL questionnaires in the following order : QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death.

Other: Quality Of Life questionnaires completion

Interventions

Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E. MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D.

Arm AArm BArm CArm D

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Palliative advanced cancer patient (Palliative chemotherapy, analgesic radiotherapy, surgery of comfort accepted).
  • All cancer locations and cancer type
  • Patient having the knowledge of their palliative disease stage.
  • Patient follow-up at least once a month by a palliative caregiver.
  • Age \> or = 18 years.
  • Dated and signed consent.
  • PS \> or = 2
  • Life expectation \> or = 1 month.

You may not qualify if:

  • Psychiatric Disease or cognitive disorders disrupting the trial understanding and the enlightened and voluntary consent character.
  • Patient who can not submit itself to the formal follow-up for psychological, social, family or geographical reasons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

CHU

Angers, 49933, France

Location

ICO Paul Papin

Angers, 49933, France

Location

CHU Minjoz

Besançon, 25030, France

Location

Institut Bergonié

Bordeaux, 33076, France

Location

Centre Hospitalier

Cholet, 49325, France

Location

Centre Georges François Leclerc

Dijon, 21079, France

Location

Centre Oscar Lambret

Lille, 59020, France

Location

Centre Val d'Aurelle Paul Lamarque

Montpellier, 34298, France

Location

Centre Antoine Lacassagne

Nice, 06189, France

Location

Centre Alexis Vautrin

Vandœuvre-lès-Nancy, 54511, France

Location

Related Publications (1)

  • Poirier AL, Kwiatkowski F, Commer JM, D'Aillieres B, Berger V, Mercier M, Bonnetain F. Health-related quality of life in cancer patients at the end of life, translation, validation, and longitudinal analysis of specific tools: study protocol for a randomized controlled trial. Trials. 2012 Apr 20;13:39. doi: 10.1186/1745-6215-13-39.

MeSH Terms

Conditions

NeoplasmsDeath

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jean-Marie Commer, MD

    Institut Cancerologie de l'Ouest

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 16, 2011

First Posted

March 7, 2012

Study Start

November 11, 2011

Primary Completion

June 6, 2019

Study Completion

June 6, 2019

Last Updated

August 1, 2023

Record last verified: 2020-11

Locations